Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel
György Nagy,
David Szabo,
Alexandra Balogh,
Laszlo Gopcsa,
Laura Giba-Kiss,
Gergely Lakatos,
Melinda Paksi,
Marienn Reti,
Peter Takacs,
Pearl van Heteren,
Gregor Zadoyan,
Silke Holtkamp,
Toon Overstijns,
Stefan Miltenyi,
Peter Remenyi
Affiliations
György Nagy
National Institute of Locomotor Diseases and Disabilities, Budapest, Hungary
We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.
